SCHEMBL14968994

SCHEMBL14968994

CCOC(=O)c1n[nH]c(=O)n(-c2ccc(F)cc2)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.51
LMNA P02545 2/20 0.51
RAB9A P51151 1/20 0.51
POLB P06746 3/20 0.48
GABRA2 P47869 1/20 0.47
GABRB2 P47870 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPT P10636 2/20 0.47
APP P05067 1/20 0.47
ALDH1A1 P00352 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HPGD P15428 2/20 0.45
HTT P42858 2/20 0.45
GAA P10253 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
SLC5A1 P13866 1/20 0.44
SLC5A2 P31639 1/20 0.44
KDM4E B2RXH2 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14969097 0.88 NPC1 (0.49) NPC1LMNARAB9APOLBGABRA2
SCHEMBL19377626 0.87 POLB (0.54) NPC1RAB9APOLBL3MBTL1MEN1
SCHEMBL14969183 0.80 KMT2A (0.46) LMNAKMT2AALDH1A1HPGDHTT
SCHEMBL14970191 0.79 NPC1 (0.55) NPC1LMNARAB9APOLBGABRA2
SCHEMBL22511532 0.76 LMNA (0.52) NPC1LMNARAB9APOLBGABRA2
SCHEMBL14969108 0.76 ALDH1A1 (0.51) NPC1LMNARAB9APOLBGABRA2
SCHEMBL19377657 0.75 POLB (0.52) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL14969155 0.75 NPC1 (0.51) NPC1LMNARAB9APOLBGABRA2
SCHEMBL1133466 0.75 TDP1 (0.66) NPC1RAB9APOLBL3MBTL1ALDH1A1
SCHEMBL680979 0.74 HPGD (0.56) NPC1LMNARAB9APOLBGABRA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421207-B2 Pyrimidinedione-based compounds as AXL, c-MET, and Mer inhibitors and methods of use thereof CMG PHARMACEUTICAL CO., LTD. (KR) 2025-09-23 US disclosed
US-20250171426-A1 PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF CMG PHARMACEUTICAL CO., LTD. (KR) 2025-05-29 US disclosed
EP-4479397-A1 PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF CMG Pharmaceutical Co., Ltd. (KR) 2024-12-25 EP disclosed
CN-119032087-A Pyrimidinedione-based compounds as AXL, C-MET and MER inhibitors and methods of use thereof CMG制药株式会社 2024-11-26 CN disclosed
CN-116283916-B Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof 中国科学院上海药物研究所 2024-06-11 CN disclosed
US-20240174666-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2024-05-30 US disclosed
EP-3843850-B1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC (US) 2023-11-15 EP disclosed
US-20230348423-A1 PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF CMG PHARMACEUTICAL CO., LTD. (KR) 2023-11-02 US disclosed
US-20230348423-A1 PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF CMG PHARMACEUTICAL CO., LTD. (KR) 2023-11-02 US disclosed
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases ARRAY BIOPHARMA INC. (US) 2023-10-10 US disclosed
US-20150210670-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS CEPHALON, INC. 2015-07-30 US disclosed
US-20150209358-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS CEPHALON, INC. 2015-07-30 US disclosed
WO-2015100117-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE CEPHALON, INC. (US) 2015-07-02 WO disclosed
WO-2015100117-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE CEPHALON, INC. (US) 2015-07-02 WO disclosed
US-9029538-B2 Uracil derivatives as AXL and c-MET kinase inhibitors IGNYTA, INC. (US) 2015-05-12 US disclosed
US-9029538-B2 Uracil derivatives as AXL and c-MET kinase inhibitors IGNYTA, INC. (US) 2015-05-12 US disclosed
US-9029538-B2 Uracil derivatives as AXL and c-MET kinase inhibitors IGNYTA, INC. (US) 2015-05-12 US disclosed
EP-2780338-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS Cephalon, Inc. (US) 2014-09-24 EP disclosed
US-20140275077-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS CEPHALON, INC. (US) 2014-09-18 US disclosed
WO-2013074633-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS CEPHALON, INC. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171426-A1 PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF MERTK, AXL, RET NPC1 4501/4885LMNA 4246/4885RAB9A 1438/4885
US-20240174666-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES RET, MERTK, MET NPC1 4222/4885LMNA 3447/4885RAB9A 755/4885
US-20150210670-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS AXL, RET, BRAF NPC1 4773/4885LMNA 3405/4885RAB9A 909/4885
US-20140275077-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS AXL, RET, BRAF NPC1 4773/4885LMNA 3405/4885RAB9A 909/4885
US-12421207-B2 Pyrimidinedione-based compounds as AXL, c-MET, and Mer inhibitors and methods of use thereof MERTK, AXL, MET NPC1 4623/4885LMNA 4427/4885RAB9A 1212/4885
US-20150209358-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS AXL, RET, BRAF NPC1 4773/4885LMNA 3405/4885RAB9A 909/4885
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases RET, MERTK, MET NPC1 4245/4885LMNA 3554/4885RAB9A 699/4885
US-20230348423-A1 PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF MERTK, AXL, MET NPC1 4623/4885LMNA 4427/4885RAB9A 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.